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In the search for a more effective chemotherapy for the treatment of Chagas disease and 
Human African trypanosomiasis, caused by Trypanosoma cruzi and Trypanosoma brucei 
parasites, respectively, the use of organometallic compounds may be a promising strategy. In 
this work, eight new heterobimetallic compounds are described including four 5-nitrofuryl 
containing thiosemicarbazones as bioactive ligands (HL1-HL4) and dppf = 1,1'-
bis(diphenylphosphino) ferrocene as organometallic co-ligand. Complexes of the formula 
[MII(L)(dppf)](PF6) with M = Pd or Pt were synthesized and fully characterized in the solid 
state and in solution, including the determination of the molecular structure of four of them 
by single crystal X-ray diffraction methods.  Most compounds showed activity in the low 
micromolar or submicromolar range against both parasites, with the platinum compounds 
being more active than the palladium analogues. Activity was significantly increased by 
generation of the M-dppf compounds (3-24 fold increase in respect to free ligands HL for T. 
cruzi and up to 99 fold increase in respect to HL for T. brucei). The inclusion of the 
organometallic co-ligand also led to lower toxicity on mammalian cells and higher selectivity 
towards both parasites when compared to the free HL compounds. The complexes interact 
with DNA and affect the redox metabolism of the parasites. Furthermore, the most active and 
selective compound of the new series, showed no in vivo toxicity on zebrafish embryos. 
Introduction
Infectious diseases represent a tremendous health burden worldwide. Among them, a group 
of seventeen communicable and poverty-related diseases, that affect about one billion people 
living in 149 countries, have received scarce attention from the pharmaceutical industry, 
probably due to low prospect of generating financial profit. These illnesses are therefore 













































































considered as neglected diseases by the World Health Organization. Our research group has 
focused its interest on two neglected parasitic diseases: American Trypanosomiasis (Chagas´ 
disease) and Human African Trypanosomiasis (sleeping sickness). These diseases are caused 
by the genetically related trypanosomatid parasites Trypanosoma cruzi and Trypanosoma 
brucei which share a high percentage of conserved genes. This fact offers the opportunity to 
develop wide spectrum drugs that might affect both parasites, leading to drugs suitable for 
the treatment of both diseases.1-3  
Chagas’ disease is an ancient and endemic illness in Latin America caused by the flagellated 
protozoan parasite Trypanosoma cruzi (T. cruzi). It is mainly transmitted to the mammalian 
host by infected blood-sucking triatomine bugs. In Latin America and the Caribbean region, 
the burden of the disease is five times greater than that of malaria. Intense migration flow 
towards the United States, Australia, Europe and Japan, has led, in the last decades, to an 
increase in the number of cases in these non-endemic regions due to other non-bug 
associated transmission ways, like blood transfusions, organ transplants and transmission 
from mother to newborn. 4-6 
Human African trypanosomiasis (HAT) or sleeping sickness is caused by two subspecies of 
Trypanosoma brucei (T. brucei): Trypanosoma brucei gambiense and Trypanosoma brucei 
rhodesiense. It is transmitted by the bite of a tsetse fly. It is restricted to poor regions of 
Africa affecting mainly people living in rural areas. T. brucei rhodesiense causes the most 
virulent form of the disease being usually fatal if left untreated. The animal disease, called 
Nagana, is also threatening since it severely affects domestic animals within the rural areas. 
7,8
New drugs are urgently needed for the treatment of both diseases. Current chemotherapy is 
quite old and suffers from several drawbacks. The most widely used drugs are Nifurtimox 
and Benznidazole for Chagas disease and Melarsoprol B and Eflornithine for HAT. They all 













































































show high toxicity and severe side effects, variable results associated with strain-specific 
differences in susceptibility and drug resistance. Additionally, prolonged treatment regimens 
are required.6,8 
The development of metal-based drugs has shown to be a promising approach in the search 
for pharmacological answers to parasitic diseases. Prospective metal-based drugs against 
highly prevalent parasitic illnesses have been identified. Among them, some ferrocenyl 
derivatives and other organometallics have shown promising results. 9-16 In this context, our 
main design strategy has been to develop metal compounds with known bioactive molecules 
as ligands, particularly bioactive 5-nitrofuryl containing thiosemicarbazones (Fig. 1). These 
compounds, containing the 5-nitrofurane pharmacophore moiety, were obtained as analogs of 
the reference antitrypanosomal drug Nifurtimox. Although they showed very good activities 
in vitro against T. cruzi, they were also rather toxic against mammalian cells.17 The 
mechanism of action of these compounds includes the reduction of the nitro group to a nitro 
anion by parasite enzymes generating free radical species (ROS) that are very toxic to T. 
cruzi.17 In order to improve the pharmacological properties of these organic compounds and 
to modulate biologically relevant physicochemical properties of their metal complexes, more 
than eighty classical and organometallic compounds have been developed till now. Metal 
compounds were rationally designed by modifying the metal center and the metal ion 
oxidation state and including different organometallic cores and different co-ligands.9 
On the other hand, in the search for new drugs against trypanosomatid parasites we 
successfully developed some very interesting ferrocenyl prospective anti-T. cruzi drugs 
including the bioactive ligand pyridine-2-thiolato-1-oxide. 18 
All these antecedents prompted us to develop a new family of palladium and platinum 
compounds with 5-nitrofuryl containing thiosemicarbazones as ligands and including an 
organometallic ferrocenyl moiety (Fig. 1). Palladium and platinum were selected based on 













































































our previous promising results as well as the proved importance of these metal ions in the 
medicinal chemistry field 14,18,19 In this work, eight 1,1'-bis(dipheny1phosphino) ferrocene 
(dppf) compounds, [MII(L)(dppf)](PF6), where M = palladium or platinum and HL = 5-
nitrofuryl thiosemicarbazones HL1-HL4 (Fig. 1), were synthesized and fully characterized in 
the solid state and in solution. The new compounds were evaluated on T. cruzi 
trypomastigotes and bloodstream T. brucei as well as on endothelial mammalian cells taken 
as mammalian cell model. The toxicity of the most active and selective compound of the 
series was also evaluated in vivo on zebrafish embryos. To get insight into the probable 
mechanism of action of the new compounds, interaction with biomolecules and generation of 
intra-parasite ROS were also studied. 
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Fig. 1. Scheme of synthesis of the new [MII(L)(dppf)](PF6) complexes, where M = Pd 
or Pt and HL1-HL4 = 5-nitrofuryl containing thiosemicarbazones. 
Experimental section
General considerations 
All common laboratory chemicals were purchased from commercial sources and used 
without further purification. The thiosemicarbazone ligands HL were prepared as previously 
reported.17 [MCl2(dppf)] precursors were synthesized according to a previously reported 













































































procedure by heating for 30 min an equimolar mixture of [MCl2(dmso)2] and dppf  in 
CHCl3.20
Chemical and Physical Measurements 
C, H and N analyses were performed with a Thermo Scientific Flash 2000 elemental 
analyzer. FTIR spectra (4000 - 400 cm–1) of the complexes and the HL compounds were 
measured as KBr pellets with a Shimadzu IR Prestige-21 instrument. Conductimetric 
measurements were done over time (5 days) at 25 oC in 10−3 M DMSO solutions using a 
Conductivity Meter 4310 Jenway to determine the type of electrolyte and to assess the 
stability of the complexes in such medium.21 1H NMR and 13C NMR spectra were recorded 
in DMSO-d6 at 30 oC on a Bruker DPX-400 instrument (at 400 MHz and 100 MHz, 
respectively). Homo-nuclear (COSY) and hetero-nuclear (2D-HETCOR) correlation 
experiments (HSQC: hetero-nuclear single quantum correlation and HMBC: hetero-nuclear 
multiple bond correlation) were carried out with the same instrument. Tetramethylsilane was 
used as the internal standard and chemical shifts are reported in ppm. A LCQ Fleet™ Ion 
Trap Mass Spectrometer from Thermo Scientific was used to measure ESI-MS spectra of 
methanolic solutions of the complexes in the positive and negatives modes. Cyclic 
voltammograms were obtained with an Epsilon Electrochemical Analyzer. A glassy carbon 
electrode was employed as working electrode, a platinum wire was used as counter electrode 
while a Ag/AgCl electrode was used as reference electrode. A standard electrochemical three 
electrode cell of 10 mL volume completed the system. Measurements were carried out at 
room temperature in 1 mM acetonitrile solutions of the compounds using tetrabutyl amonium 
hexafluorophosphate (ca. 0.1 M) as supporting electrolyte. Solutions were deoxygenated via 
purging with nitrogen for 15 min, prior to the measurements. 













































































Syntheses of [M(L)(dppf)](PF6), where M = Pd(II) or Pt(II) and HL = 5-nitrofuryl 
containing thiosemicarbazones HL1-HL4
The heterobimetallic compounds were synthesized by the following procedure: 50 mg of the 
precursor [MCl2(dppf)]CHCl3 (0.059 mmol [PdCl2(dppf)]CHCl3 or 0.053 mmol 
[PtCl2(dppf)]CHCl3) were dissolved in 10 mL methanol. To this solution, an equimolar 
amount of HL (13 mg HL1, 13 mg HL2, 14 mg HL3 and 17 mg HL4 for the Pd compounds 
and 11 mg HL1, 12 mg HL2, 13 mg HL3 and 15 mg HL4 for the Pt compounds) dissolved 
in 5 mL methanol was added. The mixture was stirred at room temperature for 1 h. The 
solution volume was reduced to 5 mL and then kept in the refrigerator. After adding NaPF6 
dissolved in a minimal volume of methanol (46 mg, 0.27 mmol) the solution was kept again 
in the refrigerator during 24 h. Pd compounds were isolated as brown solids and the Pt 
analogues as orange-yellow ones. The eight compounds were recrystallized from 
dichloromethane solutions of the compounds by adding hexane. 
[PdL1(dppf)](PF6)·CH2Cl2, Pd-dppf-L1 Yield: 40 mg, 61%. Found: C, 44.52; H, 3.30; 
N, 5.08. Calc. for C41H35Cl2F6FeN4O3P3PdS: C, 44.62; H, 3.20; N, 5.08. ESI MS m/z: 
[Calculated (Found)]: 873.01 (873.18) [PdL1(dppf)]+, 100%; 144.96 (144.82) PF6-, 
100%. FTIR (KBr, cm-1): 1605, ν(C = N); 1353, νs(NO2); 1098, ν(N-N); 810, δ(NO2 + 
furan); 842, ν(P-F); 558, δ(FPF); 1480, 1437, 1090, 698, 493, dppf. 1H NMR [DMSO-
d6, Me4Si, /ppm]: 7.91 [m, 5, H2 + PPh2], 7.81 [m, 1, H3], 7.76 [m, 5, H9 + H10 + 
PPh2], 7.62 [m, 9, PPh2], 7.46 [m, 4, PPh2], 6.61 [s, 1 H5], 4.88 [s, 2, Hc], 4.77 [s, 2, 
Hb], 4.62 [s, 2, Ha], 3.86 [s, 2, Hd]. 13C NMR [DMSO-d6, /ppm]: 174.9 (C8), 140.1 













































































(C5), 135.1 (C2), 134.9 (C3), 134.7 (CH, PPh2), 134.2 (C10), 129.9 (CH, PPh2), 129.0 
(CH, PPh2), 123.1 (CH, PPh2), 77.8 (Cc), 75.8 (Cd), 75.2 (Cb), 75.1 (Ca).
[PdL2(dppf)](PF6)·2CH2Cl2, Pd-dppf-L2 Yield: 44 mg, 62%. Found: C, 42.15; H, 
3.34; N, 4.73. Calc. for C43H39Cl4F6FeN4O3P3PdS: C, 42.14; H, 3.27; N, 4.66. ESI MS 
m/z: [Calculated (Found)]: 887.03 (887.21) [PdL2(dppf)]+, 100%; 144.96 (144.84) PF6-, 
100%. FTIR (KBr, cm-1): 1591, ν(C = N); 1350, νs(NO2); 1097, ν(N-N); 810, δ(NO2 + 
furan); 844, ν(P-F); 557, δ(FPF); 1479, 1437, 1096, 696, 494, dppf. 1H NMR [DMSO-
d6, Me4Si, /ppm]: 8.23 [s, 1, H9], 7.94 [dd, J1 = 7.80 Hz and J2 = 3.80 Hz, 4, PPh2], 
7.77 [m, 4, PPh2], 7.63 [m, 9, H2 + PPh2], 7.47 [m, 4, PPh2], 7.40 [d, J = 7.54 Hz, 1, 
H3], 6.67 [s, 1 H5], 4.85 [s, 2, Hc], 4.79 [s, 2, Hb], 4.63 [s, 2, Ha], 3.89 [s, 2, Hd], 3.83 [s, 
3, H10]. 13C NMR [DMSO-d6, /ppm]: 174.5 (C8), 141.0 (C5), 135.0 (CH, PPh2), 134.2 
(CH, PPh2), 133.1 (C2), 132.9 (CH, PPh2), 129.1 (CH, PPh2), 122.7 (C3), 78.0 (Cc), 
75.8 (Cd), 75.7 (Cb), 75.1 (Ca), 33.6 (C10).
[PdL3(dppf)](PF6)·2CH2Cl2, Pd-dppf-L3 Yield: 46 mg, 64%. Found: C, 43.86; H, 
3.42; N, 4.40. Calc. For C44H41Cl4F6FeN4O3P3PdS: C, 43.44; H, 3.40; N, 4.50. ESI MS 
m/z: [Calculated (Found)]: 901.04 (901.21) [PdL3(dppf)]+, 100%; 144.96 (144.83) PF6-, 
100%. FTIR (KBr, cm-1): 1591, ν(C = N); 1345, νs(NO2); 1098, ν(N-N); 811, δ(NO2 + 
furan); 853, ν(P-F); 557, δ(FPF); 1471, 1437, 1097, 694, 500, dppf. 1H NMR [DMSO-
d6, Me4Si, /ppm]: 8.22 [s, 1, H9], 7.91 [dd, J1 = 7.10 Hz and J2 = 3.09 Hz, 4, PPh2], 
7.76 [m, 4, PPh2], 7.63 [m, 9, H2 + PPh2], 7.47 [m, 4, PPh2], 7.36 [d, J = 6.76 Hz, 1, 
H3], 6.73 [s, 1, H5], 4.81 [s, 2, Hc], 4.77 [s, 2, Hb], 4.64 [s, 2, Ha], 3.94 [s, 2, Hd], 1.11 
[t, J = 6.40 Hz, 3, H11]. 13C NMR [DMSO-d6, /ppm]: 174.5 (C8), 143.2 (C5), 135.1 
(CH, PPh2), 134.3 (CH, PPh2), 133.1 (CH, PPh2), 132.8 (C2), 129.0 (CH, PPh2), 128.9 
(C3), 77.9 (Cc), 77.6 (Cb), 76.4 (Cd), 74.9 (Ca), 14.3 (C11).













































































[PdL4(dppf)](PF6)·1.5CH2Cl2, Pd-dppf-L4 Yield: 50 mg, 71%. Found: C, 47.03; H, 
3.29; N, 4.51. Calc. for C47.5H40Cl3F6FeN4O3P3PdS: C, 46.68; H, 3.28; N, 4.58. ESI MS 
m/z: [Calculated (Found)]: 949.04 (949.21) [PdL4(dppf)]+, 100%; 144.96 (144.87) PF6-, 
100%. FTIR (KBr, cm-1): 1598, ν(C = N); 1348, νs(NO2); 1097, ν(N-N); 812, δ(NO2 + 
furan); 845, ν(P-F); 558, δ(FPF); 1480, 1438, 1099, 692, 492, dppf. 1H NMR [DMSO-
d6, Me4Si, /ppm]: 10.19 [s, 1, H9], 7.93 [m, 4, PPh2], 7.82 [m, 4, PPh2], 7.65 [m, 5, H2 
+ PPh2], 7.55 [m, 8, PPh2], 7.42 [m, 2, Horto], 7.34 [m, 3, H3 + Hmeta], 7.12 [t, J = 7.31 
Hz, 1, Hpara], 6.74 [s, 1, H5], 4.76 [s, 2, Hb], 4.69 [s, 4, Ha + Hc], 4.16 [s, 2, Hd]. 13C 
NMR [DMSO-d6, /ppm]: 173.2 (C8), 142.7 (C5), 135.4 (CH, PPh2), 134.4 (CH, PPh2), 
133.0 (C2), 133.0 (CH, PPh2), 129.8 (CH, PPh2), 129.3 (Cmeta), 128.7 (C3), 124.8 
(Cpara), 121.5 (Corto), 77.6 (Cc), 76.3 (Cd), 75.1 (Ca), 74.4 (Cb).
[PtL1(dppf)](PF6)·2CH2Cl2, Pt-dppf-L1 Yield: 47 mg, 70%. Found: C, 40.08; H, 3.02; 
N, 4.41. Calc. for C42H37Cl4F6FeN4O3P3PtS: C, 39.50; H, 2.90; N, 4.39. ESI MS m/z: 
[Calculated (Found)]: 962.07 (962.22) [PtL1(dppf)]+, 100%; 144.96 (144.87) PF6-, 100%. FTIR 
(KBr, cm-1): 1608, ν(C = N); 1346, νs(NO2); 1098, ν(N-N); 810, δ(NO2 + furan); 841, 
ν(P-F); 558, δ(FPF); 1480, 1437, 1099, 695, 498, dppf. 1H NMR [DMSO-d6, Me4Si, 
/ppm]: 8.13 [s, br, H9 + H10], 7.95 [m, 4, PPh2], 7.87 [d, J = 4.20 Hz, 1, H2], 7.77 [m, 
1, H3], 7.75 [m, 4, PPh2], 7.62 [m, 8, PPh2], 7.47 [m, 4, PPh2], 6.93 [s, 1, H5], 4.76 [s, 
4, Hb + Hc], 4.60 [s, 2, Hd], 3.90 [s, 2, Ha]. 13C NMR [DMSO-d6, /ppm]: 176.4 (C8), 
141.8 (C5), 135.1 (CH, PPh2), 135.1 (C2), 134.8 (C3), 134.2 (CH, PPh2), 133.0 (C10), 
129.3 (CH, PPh2), 129.1 (CH, PPh2), 77.2 (Cc), 76.3 (Ca), 75.7 (Cb), 74.9 (Cd).
[PtL2(dppf)](PF6)·2CH2Cl2, Pt-dppf-L2 Yield: 46 mg, 68%. Found: C, 40.00; H, 3.19; 
N, 4.36. Calc. for C43H39Cl4F6FeN4O3P3PtS: C, 39.99; H, 3.03; N, 4.34. ESI MS m/z: 
[Calculated (Found)]: 976.9 (976.29) [PtL2(dppf)]+, 100%; 144.96 (144.82) PF6-, 100%. FTIR 
(KBr, cm-1): 1592, ν(C = N); 1349, νs(NO2); 1094, ν(N-N); 812, δ(NO2 + furan); 849, 













































































ν(P-F); 558, δ(FPF); 1479, 1437, 1096, 693, 495, dppf. 1H NMR [DMSO-d6, Me4Si, 
/ppm]:  8.44 [s, 1, H9], 7.94 [dd, J1 = 7.37 Hz and J2 = 3.43 Hz, 4, PPh2], 7.75 [m, 4, 
PPh2], 7.62 [m, 9, H2 + PPh2], 7.47 [m, 5, H3 + PPh2], 7.06 [s, 1, H5], 4.75 [s, 2, Hc], 
4.71 [s, 2, Hb], 4.64 [s, 2, Ha], 3.97 [s, 2, Hd], 2.87 [s, 3, H10]. 13C NMR [DMSO-d6, 
/ppm]: 177.7 (C8), 142.7 (C5), 135.2 (CH, PPh2), 134.3 (CH, PPh2), 133.1 (C2), 129.7 
(CH, PPh2), 129.1 (CH, PPh2), 129.1 (C3), 77.0 (Cb), 76.0 (Cd), 75.4 (Cc), 75.0 (Ca), 
34.1 (C10).
[PtL3(dppf)](PF6)·CH2Cl2, Pt-dppf-L3 Yield: 47 mg, 72%. Found: C, 41.96; H, 3.25; 
N, 4.59. Calc. for C43H39Cl2F6FeN4O3P3PtS: C, 42.32; H, 3.20; N, 4.59. ESI MS m/z: 
[Calculated (Found)]: 990.11 (990.29) [PtL3(dppf)]+, 100%; 144.96 (144.83) PF6-, 
100%. FTIR (KBr, cm-1): 1591, ν(C = N); 1343, νs(NO2); 1098, ν(N-N); 812, δ(NO2 + 
furan); 842, ν(P-F); 558, δ(FPF); 1476, 1437, 1097, 694, 502, dppf. 1H NMR [DMSO-
d6, Me4Si, /ppm]: 8.43 [s, 1, H9], 7.94 [dd, J1 = 7.35 Hz and J2 = 3.02 Hz, 4, PPh2], 
7.75 [m, 4, PPh2], 7.60 [m, 9, H2 + PPh2], 7.45 [m, 4, PPh2], 7.40 [d, J = 6.75 Hz, 1, 
H3], 7.05 [s, 1, H5], 4.75 [s, 2, Hb], 4.69 [s, 2, Hc], 4.62 [s, 2, Ha], 4.00 [s, 2, Hd], 1.11 
[t, J = 6.37 Hz, 3, H11]. 13C NMR [DMSO-d6, /ppm]: 175.9 (C8), 142.7 (C5), 135.6 
(CH, PPh2), 134.9 (CH, PPh2), 132.9 (C2), 130.5 (CH, PPh2), 128.9 (C3), 128.8 (CH, 
PPh2), 77.1 (Cc), 76.3 (Cd), 75.6 (Cb), 75.2 (Ca), 13.6 (C11).
[PtL4(dppf)](PF6)·CH2Cl2, Pt-dppf-L4 Yield: 50 mg, 74%. Found: C, 44.45; H, 3.22; 
N, 4.36. Calc. for C47H39Cl2F6FeN4O3P3PtS: C, 44.50; H, 3.10; N, 4.42. ESI MS m/z: 
[Calculated (Found)]: 1038.11 (1038.23) [PtL4(dppf)]+, 100%; 144.96 (144.87) PF6-, 
100%. FTIR (KBr, cm-1): 1597, ν(C = N); 1343, νs(NO2); 1096, ν(N-N); 812, δ(NO2 + 
furan); 841, ν(P-F); 558, δ(FPF); 1480, 1438, 1099, 695, 496, dppf. 1H NMR [DMSO-
d6, Me4Si, /ppm]: 10.40 [s, 1, H9], 7.94 [m, 4, PPh2], 7.81 [m, 4, PPh2], 7.64 [m, 5, H2 
+ PPh2], 7.54 [m, 8, PPh2], 7.41 [m, 3, H3 + Horto], 7.34 [t, J = 7.05 Hz, 2, Hmeta], 7.14 













































































[d, J = 7.37 Hz, 1, Hpara], 7.07 [s, 1, H5], 4.73 [s, 2, Hb], 4.68 [s, 2, Hd], 4.56 [s, 2, Hc], 
4.22 [s, 2, Ha]. 13C NMR [DMSO-d6, /ppm]: 179.1 (C8), 142.5 (C5), 135.3 (CH, PPh2), 
134.9 (CH, PPh2), 134.3 (C2), 132.4 (CH, PPh2), 130.0 (CH, PPh2), 129.4 (Cmeta), 128.8 
(C3), 128.7 (Cpara), 128.5 (Corto), 77.8 (Cd), 77.7 (Cb), 75.6 (Cc), 73.9 (Ca).
DMSO solutions of all the complexes (10−3 M) showed molar conductivity (ΛM) values 
between 22 and 28 Scm2mol-1.
X-ray diffraction study of [M(L)(dppf)](PF6) compounds, where M = Pd(II) or Pt(II) 
Single crystals suitable for structural X-ray diffraction studies of four of the compounds, 
namely [PdII(L2)(dppf)](PF6), [PtII(L1)(dppf)](PF6), [PdII(L3)(dppf)](PF6) and 
[PtII(L3)(dppf)](PF6), were obtained by slow diffusion of hexane into dichloromethane 
solutions of the complexes. The measurements were carried out on an Oxford Xcalibur 
Gemini, Eos CCD diffractometer with graphite-monochromated MoKα ( = 0.71073 Å) 
radiation. X-ray diffraction intensities were collected ( scans with  and κ-offsets), 
integrated and scaled with CrysAlisPro suite of programs.22 The unit cell parameters were 
obtained by least-squares refinement (based on the angular settings for all collected 
reflections with intensities larger than seven times the standard deviation of measurement 
errors) using CrysAlisPro. Data were corrected empirically for absorption employing the 
multi-scan method implemented in CrysAlisPro. The structures were solved by intrinsic 
phasing with SHELXT and the molecular model refined by full-matrix least-squares 
procedure with SHELXL of the SHELX suite of programs.23,24 
The same space group and the close values of the cell constants indicated that 
[Pt(L3)(dppf)](PF6) complex is isomorphic to the palladium analogue. In fact, an initial 
molecular model assuming the same positions of non-H atoms as in [Pd(L3)(dppf)](PF6) 













































































crystal with the identity of the metal changed to platinum lead to smooth convergence of the 
structural parameters for this latter compound during the least-squares refinement against the 
corresponding X-ray data set.
The hydrogen atoms were positioned on stereo-chemical basis and refined with the riding 
model. The methyl group in [Pd(L2)(dppf)](PF6) and in the isomorphic [M(L3)(dppf)](PF6) 
(M = Pd, Pt) complexes was refined as a rigid group allowed to rotate around the 
corresponding N-CH3 or C-CH3 bond such as to maximize the sum of the residual electron 
density at the calculated H-positions; as a result it converged to staggered angular 
conformation. Crystal data and structure refinement results are summarized in Table S1. 
Crystallographic structural data have been deposited at the Cambridge Crystallographic Data 
Centre (CCDC). Enquiries for data can be directed to: Cambridge Crystallographic Data 
Centre, 12 Union Road, Cambridge, UK, CB2 1EZ or (e-mail) deposit@ccdc.cam.ac.uk or 
(fax) +44 (0) 1223 336033. Any request to the Cambridge Crystallographic Data Centre for 
this material should quote the full literature citation and the reference numbers CCDC 
1547863 [Pd(L2)(dppf)](PF6), CCDC 1547864 [Pt(L1)(dppf)](PF6), CCDC 1422927 
[Pd(L3)(dppf)](PF6) and CCDC 1422928 [Pt(L3)(dppf)](PF6). 
Lipophilicity studies 
Reversed-phase thin layer chromatography (TLC) experiments were done on precoated TLC 
plates SIL RP-18W/UV254 and eluted with MeOH:DMF:H2O (65:5:30 v/v/v). Stock solutions 
were prepared in pure methanol (Aldrich) prior to use. The plates were developed in a closed 
chromatographic tank, dried and the spots were located under UV light. The Rf values were 
averaged from two to three determinations, and converted to RM via the relationship: RM = 
log10 [(1/Rf) –1].25, 26














































































Viability on T. cruzi (Dm28c clone) trypomastigotes. Viability assays were done by using 
the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) reduction method 
as previously described.27,28 Briefly, 1107 trypomastigotes (see ESI for details) were 
incubated in fetal bovine serum-RPMI culture medium at 37 °C for 24 h with and without the 
complexes under study at different concentrations. An aliquot of the parasite suspension was 
extracted and it was incubated in a flat-bottom 96-well plate and MTT was added at a final 
concentration of 0.5 mg/mL, incubated at 28 °C for 4 h, and then solubilized with 10% 
sodium dodecyl sulfate 0.1 mM HCl and incubated overnight. Formazan formation was 
measured at 570 nm with the reference wavelength at 690 nm in a multiwell reader 
(Biochrom® Asys Expert Plus, Biochrom, USA). Untreated parasites were used as negative 
controls (100 % of viability). Finally, a non-linear regression analysis, using Log 
concentration vs normalized response fit, by Graph Pad prism® software was performed. 
Viability assays for T. brucei. A 200 µL cell suspension containing 5 x 105 parasites/mL 
(bloodstream T. b. brucei , strain 427, cell line 449 expressing an ectopic copy of the redox 
biosensor hGrx-roGFP2, see ESI for details) in exponential growth phase were seeded per 
well in a 96-well culture plate and 2 µL of each compound prepared at different 
concentrations in 100 % v/v DMSO were added. Control wells included cells treated with 1 
% v/v DMSO or 12.5-15 µM Nifurtimox. After 24 h incubation, 100 µL from each well were 
transferred to a tube containing 200 µL of sterile PBS with glucose 1 % (w/v). Prior to 
analysis by flow cytometry, propidium iodide (PI) was added at a final concentration of 2 
μg/mL and used as a viability marker. Samples were analyzed with a C6Accuri flow 













































































cytometer (BD) using a 488 nm laser and the following filters λem= 530/40 nm and λem= 
613/30 nm for GFP and PI signal, respectively. The data were processed and analyzed with 
the C6Accuri software, where cell viability was calculated as follows: viability (%) = 100  
(number of cells for compound Y at concentration X/ number of cells in the DMSO-treated 
control). For the selected compounds, the IC50 was determined using a 7-point inhibition plot 
with each concentration (0.01 to 100 µM) tested in triplicate.29,30 
Cytotoxicity on endothelial mammalian cells. Viability assays were performed on 
endothelial cell lines EA.hy926 (permanent human cell line derived by fusing human 
umbilical vein endothelial cells–HUVEC with human lung cells-A549, see ESI for details) 
by using the MTT reduction method as previously described for T. cruzi trypomastigotes 
assay (see above).
In vivo toxicity on zebrafish (Danio rerio) larvae. Two zebrafish adult males and females 
were placed the night before spawning in breeding tanks to let them cross using glass 
marbles as spawning substrate. Collected fertilized eggs were maintained in Petri dishes with 
E3 embryo medium (5mM NaCl, 0.17 mM KCl, 0.33 mM CaCl2, 0.33 mM Mg2SO4 and 
0.0001 % methylene blue) at 28 °C. 72 h post fertilization, zebrafish embryos were placed in 
96-well plates (3 embryos per well) containing 225 µL of E3 medium and incubated for 
additional 24 h at 28°C. [Pt(L3)(dppf)](PF6) was tested at 1, 10 and 100 µM concentrations 
in a total 250 µL/well volume. DMSO at a 1 % final concentration was used to avoid 
compound precipitation. Viability was assessed by presence of heartbeat under stereoscopic 
microscope observation after 48 h treatment.













































































Insight into the mechanism of action
Generation of free radical species in T. cruzi. The free radical production capacity of the 
new complexes was assesed in the parasite using ESR (electron spin resonance) with DMPO 
(5,5-dimetyl-1-pirroline-N-oxide) for spin trapping. Each tested compound was dissolved in 
DMF (N,N-dimethylformamide, spectroscopy grade, approx. 1 mM) and the solution was 
added to a mixture containing the epimastigote form of T. cruzi (Dm28c strain; final protein 
concentration 4-8 mg/mL) and DMPO (final concentration, 250 mM). The mixture was 
transferred to a 50 μL capillary. ESR spectra were recorded in the X band (9.85 GHz) using a 
Bruker ECS 106 spectrometer with a rectangular cavity and 50 kHz field modulation. All 
spectra were registered in the same scale, after 15 scans. 31,32 The ESR spectra were 
simulated using the program WinSim 2002, 0.98 version.
Respiration experiments. Dm28c strain T. cruzi epimastigotes were harvested by 500  g 
centrifugation, followed by washing and re-suspension in 0.05 M sodium phosphate buffer 
(pH 7.4) containing 0.107 M sodium chloride. Respiration measurements were carried out 
polarographycally with a Clark electrode No. 5331 (Yellow Springs Instruments, 53 YSI 
model). 32 The chamber volume was 0.6 mL and the temperature was 28 °C. Compounds, 
dissolved in DMSO, were added in 40 μM final concentration. The amount of parasite used 
was equivalent to 1.2 mg of protein/mL. Results were corrected according to the observed 
effect produced by DMSO alone.
In vitro assays with recombinant redox biosensor. Recombinant hGrx-roGFP2 protein was 
expressed and purified as previously described, pre-reduced with DTT 20 mM in PBS 
containing 1 mM EDTA for 1 h at room temperature.29,33 The excess of reducing agent was 













































































removed by gel filtration on a Sephadex G25 (PD10 column, GE-Healthcare) equilibrated 
with PBS (pH 7.4) 1 mM EDTA. Protein concentration was measured at 280 nm, where ε280 
= 23290 M1cm1 for hGrx-roGFP2. The reduced biosensor (1 µM) was treated with the 
different compounds added at 10 µM for 1 h at room temperature, and then the fluorescence 
spectra at λem= 510 nm recorded on a Cary Eclipse equipment. Controls included treatment 
of the biosensor with 10 µM reduced glutathione (GSH), 100 µM glutathione disulfide 
(GSSG) (1 h incubation) and/or 2 mM dithiotreitol (DTT) (30 min incubation) added or not 
of test compounds at 10 µM. 
DNA interaction studies
Fluorescence experiments. Experiments for competitive binding to calf thymus DNA 
(CT-DNA, SIGMA, Type Y, No. D-1501) with ethidium bromide (EB, SIGMA) were 
carried out in 10 mM Tris-HCl buffer at pH 7.4. CT-DNA solution (1 mg/mL ~ 2 
mM·nucleotide1) 34 was pre-incubated with EB (5 mM) at 4 °C for 24 h. Samples were 
prepared with a total concentration of DNA and EB of 20 μM·nuc1 and 10 μM, 
respectively, varying the total complex concentration from 1-110 μM (final DMSO 
concentration of 5 % v/v). They were incubated at 37 °C for 30 min. Fluorescence 
spectra were recorded from 520 nm to 650 nm at an excitation wavelength of 510 nm on 
a Shimadzu RF-5301PC spectrofluorimeter. Fluorescence emission intensity was 
corrected for the absorption and emission inner filter effects and the mechanism 
involved in the fluorescence quenching process for the compounds was analysed using 
the Stern-Vomer equation (see ESI for detais). 35   
Circular dichroism experiments. Calf thymus DNA was purchased from Sigma (#D3664) 
and used as received. The CT-DNA free of protein stock solution was prepared by 













































































dissolution in Tris-HCl buffer. 34,36 Circular dichroism studies in the UV range were done 
with 3 mL solutions using quartz SUPRASIL® cuvettes of 1 cm optical path. A CT-DNA 
solution (50-60 μM·nucleotide1) 34 was incubated with the compounds’ solutions in DMSO 
(5 % v/v) to obtain DNA:compound molar ratio of 1:0.5 in all cases. CD spectra were 
collected from 240 nm to 300 nm with 5 accumulations and a scan speed of 50 nm/min. CD 
studies in the visible range were done with 3.5 mL solutions using quartz cuvettes of 2 cm 
optical path, 200 μM·nucleotide1 CT-DNA concentration and 20 % v/v of DMSO in the 
medium (molar ratio 1:0.5). The spectra were collected from 300 nm to 600 nm, with 3 
accumulations and a 200 nm/min scan speed. The CD spectra were recorded at 25°C on a 
Jasco J-720 spectropolarimeter with UV–vis (200–700 nm) photomultipliers (EXEL-308). 
For selected samples spectra were re-measured with time, to evaluate changes with time, 
which did not occur.
BSA interaction studies
Fluorescence experiments. The bovine serum albumin (BSA, Sigma Aldrich) stock solution 
was prepared by gently dissolving the protein in PBS buffer (phosphate buffer saline, 10 
mM, pH 7.4).37 The BSA concentration in PBS buffer was kept constant in all samples (1 
μM), while the complex concentration was increased from 0 μM to 20 μM (final DMSO 
concentration of 2 % (v/v)), to obtain the desired protein/complex molar ratios (from 1:0 to 
1:20). The samples were incubated at 37 °C for 24 h. The fluorescence experiments were 
done on a Shimadzu RF-5301PC spectrofluorimeter using a quartz cuvette of 1 cm path 
length. Fluorescence spectra were recorded from 300 nm to 450 nm at an excitation 
wavelength of 295 nm. Fluorescence spectra were corrected for the absorption and emission 
inner filter effects.35 The mechanism involved in the fluorescence quenching process was 













































































analysed using the Stern-Volmer equation and the binding parameters were obtained using 
the Scatchard equation.38-40 (see ESI for details).
Circular dichroism experiments. The BSA stock solution was prepared by dissolution in 
PBS buffer (10 mM, pH 7.4) and the concentration of BSA was determined as previously 
described.37 The circular dichroism studies were done in the visible range with 3.5 mL 
solutions in quartz SUPRASIL® cuvettes of 2 cm optical path. A BSA solution (100 μM) 
was incubated with the compounds’ stock solutions in DMSO (15% v/v) to obtain 
BSA:complex molar ratio of 1:1 in all cases. The CD spectra were collected from 300 nm to 
600 nm with 3 accumulations and a scan speed of 200 nm/min. The CD spectra were 
recorded at 25 °C on a Jasco J-720 spectropolarimeter with UV–vis (200–700 nm) 
photomultipliers (EXEL-308). 
Results and discussion 
Synthesis and characterization of the complexes
Eight new organometallic heterobimetallic compounds of the bioactive 5-nitrofuryl 
containing thiosemicarbazone ligands HL1-HL4 with the formula [M(L)(dppf)](PF6), where 
M = Pd(II) or Pt(II), were obtained with good purities and good yields according to the 
proposed synthetic scheme shown in Fig. 1 and they were exhaustively characterized in the 
solid state and in solution.
Characterization of the complexes in the solid state













































































All complexes showed a similar FTIR absorption band pattern. Spectra for analogous Pd and 
Pt compounds were almost identical in agreement with isostructurality observed in their 
crystal structures (see below). Based on our previous experience on vibrational behavior of 
HL ligands and their metal complexes, most relevant vibration bands were tentatively 
assigned (Table S2). 41-42 Five bands corresponding to the dppf moiety were also identified as 
well as the strong stretching (PF) and bending (FPF) bands of the PF6 counterion at 
around 840 and 560 cm-1.43,44 
Crystal structure of [M(L)(dppf)](PF6) complexes, where M = Pd(II) or Pt(II). Figures 2, 
S1 and S2 show ORTEP drawings of [Pd(L2)(dppf)](PF6), [Pt(L1)(dppf)](PF6) and  
[M(L3)(dppf)](PF6) (M = Pt) complexes, respectively.45 Selected bond distances and angles 
around the metal center M (M = Pd and Pt) are compared in Table 1. The molecular 
structures are closely related to one another with the M(II) ion at the center of a nearly square 
planar P2NS environment (rms deviation of atoms from the best least-squares plane less than 
0.148 Å, with the metal at less than 0.104(2) Å from the plane). The metal is cis-coordinated 
to a bis(diphenylphosphino) ferrocene moiety acting as a bidentate ligand through the 
phosphorous atoms with M-P distances in the range 2.27 – 2.38 Å. The other cis-positions 
are occupied by a thiosemicarbazone molecule also acting as a bidentate ligand through its 
sulfur atom with M-S distances in the range 2.28 – 2.30 Å, and its nitrogen atom with M-N 
distances in the range 2.10 – 2.15 Å (see Table 1). A similar planar coordination around 
M(II) was reported for the related 1,l'-bis (dipheny1phosphino)ferrocene pyridine-2-thiolato-
1-oxide M(II) hexafluoro phosphate [M(II) = Pd, Pt] isomorphic pair of complexes, where 
the thiosemicarbazone molecule is replaced by a pyridine-2-thiolato-1-oxide anion acting as 
bidentate ligand through its sulfur [M-S distances of 2.293(2) Å (Pd) and 2.303(2) Å (Pt)] 
and oxygen [M-O distances of 2.059(6) Å (Pd) and 2.071(4) Å (Pt)] atoms, and also for 













































































[PdCl2(dppf)] complex, where a pair of chloride ions at cis-positions replace the organic 
ligand.17,43 
Promoted by delocalized π-bonding, the relative rotational freedom around the N-N σ-bond 
and the coordination to the metal, the thiosemicarbazone skeletons in [Pd(L2)(dppf)](PF6), 
[Pt(L1)(dppf)](PF6) and isomorphic [M(L3)(dppf)](PF6) compounds (M = Pd, Pt) are nearly 
planar (rms deviation of atoms from the best least-squares plane less than of 0.159 Å).
In the dppf ligands, the coordination around iron in the ferrocene moiety shows the expected 
Archimedean pentagonal anti-prism conformation with the 5-membered rings staggered to 
each other (Fe-C bond distances in the range from 1.985(4) to 2.10(1) Å). Phosphorous-
C(ph) bond distances are in the 1.80(1) -1.937(5) Å range, while P-C(Cp) lengths are in the 
range from 1.773(5) to 1.829(9) Å. 
Fig. 2. View of 
[Pd(L2)(dppf)](PF6) showing the 
non-H atoms displacement 
ellipsoids at the 30 % probability 
level. Ligand-metal interactions are 
indicated by full bonds. For clarity, 
only the thiosemicarbazone ligand 
is fully labeled and a few 
representative atoms of the 
bis(dipheny1phosphino)ferrocene 
ligand have been labeled to indicate 
the numbering scheme. For the 
same reason, the PF6 counter-ion 
was omitted.













































































Table 1.  Bond lengths [Å] and angles [°] around the metal M in [Pd(L2)(dppf)](PF6), 
[Pt(L1)(dppf)](PF6) and isomorphic [M(L3)(dppf)](PF6) (M = Pd, Pt) complexes.
[PtII(L1)(dppf)](PF6) [PdII(L2)(dppf)](PF6) [PdII(L3)(dppf)](PF6) [PtII(L3)(dppf)](PF6)
Selected bond lengths
M-N(4C) 2.100 (7) 2.144 (3) 2.151 (3) 2.126 (4)
M-S 2.304 (3) 2.2841 (9) 2.282 (1) 2.293 (1)
M-P(2) 2.312 (2) 2.3688 (9) 2.378 (1) 2.339 (1)
M-P(3) 2.269 (2) 2.2785 (9) 2.275 (1) 2.263 (1)
Selected bond Angles
N(4C)-M-P(3) 169.7 (2) 166.98 (8) 166.25 (8) 167.3 (1)
N(4C)-M-S 81.1 (2) 82.13 (8) 82.15 (8) 81.9 (1)
P(3)-M-S 89.17 (9) 87.63 (3) 87.64 (4) 88.91 (4)
N(4C)-M-P(2) 96.3 (2) 97.71 (8) 98.06 (8) 96.9 (1)
P(3)-M-P(2) 93.98 (9) 93.30 (3) 92.93 (4) 92.99 (4)
S-M-P(2) 167.1 (1) 174.03 (4) 174.86 (4) 174.61 (5)
Characterization of the complexes in solution
Molar conductivity values shown by 1 mM DMSO solutions of the complexes lie in the 
range reported for 1:1 electrolytes which is in agreement with the proposed formulae.21 No 
conductivity changes were observed during at least 5 days at 25°C. In addition, 1H NMR 
spectra were measured during the same period (see below); neither changes in intensity of the 
signals, nor new peaks due to release of free ligands were detected. Hence both data suggest 
that the complexes are stable in DMSO solution.
NMR results
1H and 13C spectra were recorded in DMSO-d6 solution. Two-dimensional NMR 
experiments, namely COSY and HSQC, aided in the assignment of the spectra. Results of the 
1H NMR experiments for the HL compounds and the corresponding complexes are included 
in Table S3. All complexes showed a similar pattern of signals corresponding to the protons 













































































of L and dppf ligands. Integration and multiplicity were in accordance with the stoichiometry 
of the compounds. Even though signals appeared quite broad in some of the obtained 
complexes, four signals corresponding to the two H atoms of the furan ring, CH=N and NH-
R protons of the thiosemicarbazone ligand were easily distinguishable. A shift of the signals 
of these protons in respect to the free HL1-HL4 compounds was observed upon coordination. 
In particular, the CH=N proton (proton 5, Table S3) at around 8 ppm in the free 
thiosemicarbazone ligands was significantly shifted in all complexes according to the 
coordination of the imine nitrogen to the metal centre. This effect was more pronounced for 
the palladium complexation than for that of platinum. 32,46 
The non-detection of the signal corresponding to H7 in the spectra of the complexes, 
observed as a singlet with integration of 1 proton in the spectra of the four free HL ligands, 
demonstrated the deprotonation of the hydrazine nitrogen upon coordination. 
Two singlets with four proton integration at 3.94 and 4.27 ppm were observed for the 
cyclopentadienyl Cp rings of the dppf free ligand. These signals have been assigned to 
equivalent Ha-Hd and Hb-Hc protons of both Cp rings (see figure in Table S3) that are 
coplanar to each other and with an average eclipsed conformation at room temperature.47,48 A 
splitting of these two signals in four singlet signals that integrate for four protons was 
observed for all the new [M(L)(dppf)](PF6) compounds, with the exception of Pt-dppf-L1 
(Table S3). In this last case only 3 singlets were observed due to the overlapping of the 
signals of Hb and Hc (at 4.76 ppm integrating four protons). This assignment was confirmed 
by 1H-1H COSY experiments where a correlation pattern Ha  Hd  Hc, Hb was observed. 
In general, the equivalence of the Cp protons in free dppf is broken upon formation of the M-
dppf-L complexes due to the loss of fluxionality caused by the geometric requirements of the 
M-P bonding in the presence of the bidentate L ligand.18,49,50 













































































At higher ppm values (7.45 – 7.95 ppm), multiplets corresponding to the protons of the PPh2 
units of the dppf moiety were observed. 
2D-HSQC experiments allowed the assignment of the 13C NMR signals (Table S4). The 
assignment of the carbon of thiocarbonyl group (-C=S) was performed directly in the 13C-
NMR spectra based on chemical shift values previously reported for other HL complexes. 
Cyclic voltammetry studies
The electrochemical properties of the complexes were investigated by cyclic voltammetry. 
The eight compounds showed similar voltammetric responses in both, cathodic and anodic 
directions. Relevant electrochemical data obtained for the compounds are summarized in 
Table 2. 











































Fig. 3. (a) Cyclic voltammogram of [PtII(L1)(dppf)](PF6) and of HL1 in the cathodic 
direction at 100 mV/s. (b) Cyclic voltammograms of [PtII(L1)(dppf)](PF6) in the anodic 
direction (0.6 – 1.5 V) at different scan rates. Inset: graph of Randles-Sevcik equation for the 
[PtII(L1)(dppf)](PF6) anodic couple.51 
Table 2. Relevant electrochemical data of the [MII(L)(dppf)](PF6) compounds, 
where M = Pd or Pt.
Compounds FeII/FeIII Couple I (HL) Couple II (HL)
E1/2 Epa Epc Epa Epc


























































































Pd-dppf-L1 1.09 -0.61 (-0.92) -0.73 (-0.80) -0.96 -0.94 (-1.02)
Pd-dppf-L2 1.09 -0.60 (-0.98) -0.70 (-0.85) -0.91 -0.96 (-1.11)
Pd-dppf-L3 1.09 -0.71 (-0.95) -0.71 (-0.84) -0.94 -0.97 (-1.10)
Pd-dppf-L4 1.08 -0.55 (-0.92) -0.65 (-0.81) -0.94 -0.92 (-1.04)
Pt-dppf-L1 1.09 -0.59 (-0.92) -0.66 (-0.80) -0.93 -1.00 (-1.02)
Pt-dppf-L2 1.09 -0.60 (-0.98) -0.67 (-0.85) -0.97 -1.03 (-1.11)
Pt-dppf-L3 1.09 -0.60 (-0.95) -0.67 (-0.84) -0.99 -1.07 (-1.10)
Pt-dppf-L4 1.09 -0.52 (-0.92) -0.61 (-0.81) -0.82 -0.91 (-1.04)
As previously stated for the free HL ligands and their metal complexes, the new compounds 
show a quasi reversible reduction process around -0.6 – -0.7 V (vs. Ag/AgCl), corresponding 
to the generation of a nitro anion radical (NO2·) by one electron reduction of the nitro group 
of the thiosemicarbazone (couple I) (Fig. 3a).32,46 Previous cyclic voltammetry studies 
demonstrated that coordination of the 5-nitrofuryl thiosemicarbazone compounds HL to 
palladium and platinum ions lead to a displacement of the potential of the nitro group – nitro 
anion radical couple to less negative values. A similar behavior was observed for this new 
series of HL compounds (Table 2). This change could be biologically relevant, since it would 
favor the generation of toxic oxygen radical species (ROS) in the parasite, initiated by 
reduction of the nitro group for the {M(dppf)} HL compounds in respect to the free ligands 
and Nifurtimox. This bioreduction could be one of the mechanisms involved in the biological 
action of the new compounds against trypanosomes.32,46
Towards more negative potentials (around – 1.0 V) all compounds showed another quasi-
reversible electrochemical process, couple III, that was assigned to the further reduction of 
the nitro group to hydroxylamine (Fig. 3a). 52,53
In the anodic direction, a reversible redox couple characteristic of the FeIII/FeII couple of the 
dppf ligand was observed at around 1.09 V for all the compounds (Fig. 3b, Table 2).18,54-56 In 
all cases the anodic and cathodic peak potentials (Epa and Epc) of this couple were 
independent of the scan rate (in the range 50 to 500 mV/s) and the ΔEp values were around 
59 mV (Fig. 3b). In addition, the ip/v1/2 values did not change when modifying the scan rate, 













































































and the ratio of cathodic to anodic peak currents (ipc/ipa) remained close to unit. This 
behaviour is typical of a reversible charge transfer process.50,57-60
Lipophilicity
Lipophilicity is a very important physicochemical property of prospective drugs that 
determines biological behaviour, particularly transmembrane transport and interaction with 
biological receptors. Therefore, its correlation with the observed biological activity is usually 
a relevant characteristic to be checked.
Since the new compounds do not show adequate solubility in water to allow the 
determination of LogP values in the conventional way, the lipophilicity was experimentally 
determined using reversed-phase TLC, where the stationary phase (precoated TLC-C18 
plates) may be considered to simulate lipids of biological membranes or receptors, and the 
mobile phase (MeOH:DMF:H2O (65:5:30 v/v/v)) resembles the aqueous biological milieu. 
The composition of the mobile phase was tuned-up in order to allow differentiating 
complexes and free thiosemicarbazone ligands according to their lipophilicity. The most 
lipophilic compounds run less in this TLC system and, therefore, the method allows to 
compare lipophilicities of free ligands with complexes and complexes among them, all 
determined in the same experimental conditions.
As expected, the lipophilicity increased from the free ligand to its metal compounds due to 
the inclusion of the {M(dppf)} moiety and also for each series of complexes (Pt-dppf-L or 
Pd-dppf-L), as the N-substituent in the thiosemicarbazone ligand changes from hydrogen to 
phenyl, i.e. from M-dppf-L1 to M-dppf-L4 (Table 3, column on the right). 
Results of biological studies













































































Anti-Trypanosoma cruzi and anti-Trypanosoma brucei in vitro activities.
Results of in vitro activity on T. cruzi trypomastigotes (Dm28c) and bloodstream T. b. brucei 
(strain 427) cell line 449 are depicted in Table 3.
Table 3.  In vitro activity (measured as the IC50 value, the half inhibitory 
concentration) against T. cruzi tripomastigotes (Dm28c) and T. brucei, cytotoxicity on 
EA.hy926 endothelial cells and selectivity index (SI) values of [M(L)(dppf)](PF6) 
complexes and HL1-HL4 (included for comparison). RM values (lipophilicity) of the 
complexes and the corresponding free ligands, determined by reversed phase TLC 





SI a T. brucei
IC50/M
SI b RM
HL1 >100 9.8  1.5c >10 1.1d >90  -1.0
[Pd(L1)(dppf)](PF6) >50 7.58  0.10 >7 0.90  0.05 >55  0.03
[Pt(L1)(dppf)](PF6) >50 3.11  0.05 >16 0.77  0.02 >65  -0.02
HL2 >100 17.4  1.9 c >6 11.0 d >9  -0.95
[Pd(L2)(dppf)](PF6) >50 1.42  0.02 >35 0.93  0.03 >54  0.07
[Pt(L2)(dppf)](PF6) >50 0.79  0.06 >63 0.60  0.03 >83  0.10
HL3 >100 18.5  1.7 c >5 17.0 d >6  -0.91
[Pd(L3)(dppf)](PF6) >50 3.6  0.05 >14 0.98  0.06 >51  0.16
[Pt(L3)(dppf)](PF6) >50 0.76  0.03 >66 0.52  0.03 >56  0.16
HL4 >100 22.7  1.6 c >4 >100 d -  -0.41
[Pd(L4)(dppf)](PF6) >50 29.4  2.03 >2 1.56  0.04 >32  0.31
[Pt(L4)(dppf)](PF6) >50 1.32  0.21 >38 1.01  0.04 >50  0.35
Nifurtimox - 20.1e - 15.0e - -
Suramin - - - 0.078e - -
a: IC50 EA.hy926 / IC50 T. cruzi 




All compounds displayed IC50 values against both parasites in the low micromolar or sub-
micromolar range, with those containing platinum presenting an overall higher activity than 
those with palladium (Table 3). The platinum-based HL2 and HL3 compounds showed the 













































































highest anti-T. brucei (IC50 = 0.60 µM and 0.52 µM, respectively) and anti-T. cruzi (0.79 and 
0.76 µM, respectively) activities. 
The new metal compounds are up to 26 times more active than the reference drug Nifurtimox 
on T. cruzi (IC50 = 20 M) and up to 30 times (IC50 = 15 M) on T. brucei.
Antiparasitic activity significantly increased by generation of the M-dppf-L compounds. A 3-
24 fold increase and up to 99-fold increase of activity with respect to free ligand HL was 
observed for T. cruzi and T. brucei, respectively (Table 3). 
In general, no correlation between antiparasitic activity (T. cruzi and T. brucei) and 
lipophilicity was observed (Table 3). In particular, the complexes containing L4 are the more 
lipophilic ones but not the more active compounds. Both Pd- and Pt-L4 compounds showed 
similar lipophilicity but quite different antiparasitic activity.
Unspecific cytotoxicity on mammalian cell model
Cytotoxicity was determined using EA.hy926 endothelial cells as mammalian cell model. 
Selectivity index values for all the complexes and free HL ligands were calculated by 
dividing the IC50 on EA.hy926 cells by the IC50 on each parasite, T. cruzi or T. brucei (Table 
3).
The new metal compounds showed selectivity indexes in the range 2-66 for T. cruzi and 32-
83 for T. brucei. Unspecific cytotoxicity of the HL1-HL4 ligands was significantly reduced 
in most of the M-dppf-L complexes (Table 3). These 5-nitrofuryl containing 
thiosemicarbazone metal compounds constitute the first group of compounds that shows  
comparable good potencies and selectivities towards two different pathogenic trypanosomes. 
A similar decrease of cytotoxicity by generation of an M-dppf complex had been observed 













































































for the previously reported pyridine-2-thiolato-1-oxide compounds in comparison with 
analogous Pd and Pt classical coordination compounds.18 
In vivo toxicity 
Zebrafish (Danio rerio) is a small cyprinid naturally found in the Ganges River in South-East 
Asia. Its high breeding rate (a single mature female lays 50–200 eggs per day), easy view of 
embryogenesis and organ development, small size, fast and external development of the 
embryos, availability of genomics databases and molecular tools and a relative high human-
gene ontology and low cost have converted it in a major model in developmental biology and 
drug discovery. In particular, zebrafish is increasingly employed as toxicological model for 
evaluating toxicity in drug screening assays.62 In the past, we and other researchers have 
successfully used this model for studying in vivo toxicity of new prospective metal-based 
drugs.63,64 
Being [Pt(L3)(dppf)](PF6) the most active and selective compound of the new series, its in 
vivo toxicity on zebrafish embryos was tested. All zebrafish embryos were alive in the 
[Pt(L3)(dppf)](PF6) whole concentration range examined (1-100 M) and no apparent 
toxicity was observed at the endpoint (48 h) of the assays. 
Insights into the mechanism of action
Production of free radicals in T. cruzi
It has been shown that the principal mechanism of anti T. cruzi action of the 5-nitrofuryl 
containing thiosemicarbazone bioactive compounds involves the intraparasite bioreduction 
leading to toxic free radicals.17,65 This mechanism of action is also retained by other 
previously reported metal complexes that include these thiosemicarbazone ligands.32,46,66













































































As previously stated, the first step of this mechanism involves the one electron reduction of 
the nitrofuran moiety. The cyclic voltammetry studies showed that this reduction could be 
more easily achieved for the M-dppf-L complexes than for the free thiosemicarbazone 
compounds, hence possibly facilitating the bioreduction mechanism. In order to assess the 
free radical production capacity of the new heterobimetallic compounds, ESR experiments 
were carried out after incubating the compounds with T. cruzi (Dm28c strain) epimastigotes. 
DMPO was added as spin trapping agent to detect free radical species having short half-time 
lives. All complexes showed a similar line pattern in the ESR spectra that is exemplified by 
the ESR spectrum obtained in the presence of [PdII(L4)(dppf)](PF6), displayed in Fig. S3. 
In all cases, a ten line spectral pattern was observed. These lines correspond to two different 
DMPO spin adducts. One of these spin adducts (marked with + in Fig. S3) corresponds to the 
trapping of a carbon centered radical by DMPO showing the characteristic six line pattern (aN 
= 16.1 G and aH  = 23.1 G).67 This trapped species could be related to the bioreduction of the 
complexes, generating a nitroheterocyclic radical. The second spin adduct (*, Fig. S3) 
consisting of four lines of 1:2:2:1 intensities (aN = aH = 14.8 G) corresponds to DMPO-OH 
species. Intracellular hydroxyl radical species would arise due to intraparasite redox cycling 
processes.
These results confirm the biological free radical production capacity of the M-dppf-L 
complexes and their subsequent participation in redox cyclic processes generating reactive 
oxygen species. It can then be concluded that the complexes would maintain the mode of 
action of the free thiosemicarbazone ligands. 
Effect on the oxygen consumption of T. cruzi













































































The involvement of the M-dppf-L complexes in redox cycling process should increase the 
parasite oxygen consumption. This effect has been previously reported for the 
thiosemicarbazone compounds and other complexes that include them.32,46,65 Thus, the effect 
of the obtained complexes on the oxygen uptake of T. cruzi epimastigotes was measured and 
results are shown in Table S5.
All complexes modified oxygen uptake by the parasites, increasing oxygen consumption. 
These results are in accordance with the detection of free radical species in the ESR 
xperiments and therefore confirm the bioreduction of the complexes and their participation in 
redox cyclic processes. However, no correlation between oxygen uptake and anti-T. cruzi 
activity was observed indicating that other mechanisms are also involved in parasites´ death.  
Redox changes in T. brucei
Ferrocenes are known to undergo one electron oxidation, which in biological systems may 
lead to the formation of radicals and the concomitant oxidation of macromolecules, with the 
thiol groups of proteins and low molecular metabolites (i.e. glutathione) being important 
nucleophilic targets. The potential redox activity underlying the killing mechanism of 
trypanosomes by ferrocene complexes was investigated using T. brucei parasites expressing 
a redox biosensor. The biosensor (hGrx-roGFP2) is based on human glutaredoxin (hGrx) 
coupled to a redox sensitive green fluorescence protein (roGFP2) that is able to translate 
changes in the glutathione/glutathione disulfide (GSH/GSSG) ratio into changes in its 
fluorescence intensity (e.g. its oxidation leads to a decrease in its fluorescence intensity at 
510 nm upon excitation at 488 nm). An increase in this ratio indicates oxidation of the redox 
biosensor to its disulfide form.33 Parasites expressing the redox biosensor were incubated for 
24 h with the complexes at concentrations close to or above their IC50 values (0.37, 1.1 and 
3.30 µM). Only Pt-dppf-L1 and Pt-dppf-L2 added at 4- and 5-fold, respectively, of their IC50 













































































values produced almost 30 % oxidation of the biosensor, which is equivalent to the oxidation 
caused by 250 µM H2O2, under the same experimental conditions (Fig. S4). 
In vitro assays performed with the recombinant biosensor and reduced glutathione, 
confirmed that both Pt compounds were not capable to act as direct oxidants of these 
molecules (Fig. S5). Taken together, these experiments clearly support that the intracellular 
oxidative shift triggered by Pt-dppf-L1 and Pt-dppf-L2 complexes is not consequence of a 
direct action of these compounds on the redox probe or glutathione but most likely mediated 
by secondary oxidative species generated by them (ROS) upon reductive activation and/or by 
inhibition of important components of the parasite redox system.68 
In contrast, the Pd-dppf-L1 complex produced a 40 % increase in fluorescence intensity of 
the biosensor. The physiological cause behind this phenomenon remains unknown but given 
the specificity of the redox biosensor for the couple GSH/GSSG 29, it may indicate a strong 
reductive stress exerted by Pd-dppf-L1.
DNA interaction studies
Fluorescence experiments 
The fluorescent DNA probe, ethidium bromide (EB), was used to access the interaction of 
the M-dppf-L complexes with DNA. EB is a conjugate planar molecule with weak intrinsic 
fluorescence emission at the selected excitation wavelength and at pH 7.4 in Tris-HCl 
buffer/2 % DMSO, its spectrum shows an emission maximum at 601 nm (λexc. = 510 nm). 
Intercalation of EB into double stranded DNA induces an increase of the fluorescence 
quantum yield.69 In the spectrum of the {DNA-EB} adduct the emission maximum is shifted 
to 594 nm under these experimental conditions. Neither DNA nor the complexes are 
fluorescent in these experimental conditions, and no fluorescence emission results from 













































































compounds´ direct interaction with DNA. Obtained results for the titration of the {DNA-EB} 
adduct with the complexes are summarized in Fig. 4. 




































Fig. 4. Relative fluorescence intensity (%) at λem. = 594 nm with increasing complex 
concentration obtained for (a) palladium and (b) platinum complexes.  (CDNA = 20 μM, CEB = 
10 μM, samples prepared in 2% DMSO/Tris-HCl medium, 30 min incubation at 37 °C). 
Squares: L1 complexes, circles: L2 complexes, triangles: L3 complexes, diamond: L4 
complexes. 
A quenching of the emission of {DNA-EB} adduct up to 80 % was observed upon increasing 
the complexes´ concentration. The extent of the quenching was quite similar for all 
complexes but those that include L1 as ligand give rise to the highest quenching. A 
bathochromic shift of 7 nm, changing the λmax. from 594 to 601 nm (characteristic of the free 
EB spectrum, Fig. S6) was also observed as well as the development of two isobestic points. 
These results are consistent with an EB displacement from the {DNA-EB} adduct brought 
upon by the binding of  the complexes to DNA in an intercalative-like manner, or by  
inducing DNA conformational changes which cause the disruption of EB binding.













































































The fluorescence quenching process for M-dppf-L complexes was studied by Stern-Volmer 
analysis. This equation predicts a linear plot of IF0/IF for a homogeneously emitting system. 
All complexes show a positive deviation from linearity at high concentration that is 
frequently observed when the extent of quenching is relatively large.35 In the low 
concentration range of the complexes (typically up to 40 μM), the plot IF0/IF is linear and the 
KSV constant was calculated for each system (Table 4).
Table 4. Stern-Volmer constants obtained for 
[MII(L)(dppf)](PF6) compounds for the competitive 
binding to {DNA-EB} in 2% DMSO/Tris-HCl buffer









Results show that all the tested complexes interact with DNA with somewhat similar 
affinities. It should be stated that obtained KSV values are of the same order than those 
previously reported for [MIICl(L)(PTA)](PF6) (M = Pd or Pt, PTA = 1,3,5-triaza-7-
phosphaadamantane) complexes which showed an intercalating-like mode of DNA 
interaction.70
DNA-binding study by CD spectroscopy













































































Circular dichroism (CD) is a spectroscopic technique used to study systems which present 
intrinsic or induced chirality and may be used to assess the affinity and binding mode of 
small molecules, such as metal compounds, to chiral biomolecules.71,72 DNA is a chiral 
molecule producing a characteristic CD spectrum in the 200-300 nm range. In particular, CT-
DNA shows a typical spectrum for right-handed B form consisting of two main bands: a 
positive one centred at ~275 nm and a negative one at ~245 nm, due to base stacking and 
right-handed helicity, respectively.73 Changes in the CD bands in this spectral range are 
useful to detect DNA conformational changes, damage and/or cleavage.71,74,75 In addition, 
even if the complexes are not chiral and thus present no CD signal, their association with 
DNA may give rise to an induced circular dichroism spectra (ICD) in the range of the 
complexes´ absorption bands.
The conformational changes of CT-DNA induced by the M-dppf-L complexes were 
monitored by CD spectroscopy. As DMSO was used as solvent to allow dissolving suitable 
amounts of the complexes, the CD spectra could only be measured in the UV range between 
240-300 nm (Fig. S7). CD spectra were also measured between 300-600 nm, where DNA has 
no CD bands (Fig. S8). 
Upon mixing DNA with the complexes, changes in the CD spectra were immediately 
observed in the range 240-300 nm, with all complexes inducing a decrease in the positive 
band of the CD spectrum of DNA (Figures S9-S12). These results suggest that the complexes 
interact with CT-DNA inducing conformational changes in its structure. The complexes that 
include the L1 ligand showed the greatest effect on this band.
These results are in accordance with those observed by fluorescence experiments, where the 
highest quenching effects were also found for the complexes containing L1. M-dppf-L1 
complexes having the smallest substituents in the terminal amine group possibly penetrate 













































































more easily the biomolecule affecting, for example, base stacking and generating 
conformational changes on DNA. It is also plausible that the presence of –NH2 moiety 
instead of –NHR (R = Me, Et or Ph) allows establishing stronger hydrogen bonds with 
suitable groups of DNA, such as phosphates.
In the CD spectra measured in the visible range, two negative bands at ~330 nm and ~450 
nm were observed. The presence of these bands corresponds to induced chirality in bands of 
the metal complexes, probably due to the formation of adducts between DNA and the 
complexes.72,76 In fact, the absorption spectra of the complexes, measured in similar 
conditions (5 % DMSO in Tris-HCl buffer), depict two reasonably strong absorption bands at 
similar wavelength values. As the extinction coefficients of bands with max in the 425-450 
nm range of the Pd- and Pt-dppf-L complexes are similar for all complexes (ca.: 1.2-1.4104 
M1 cm1), the intensity of the observed induced CD (ICD) bands show that the complexes 
that include the L2 ligand either have the strongest interaction with the DNA, or bind to CT-
DNA closer to its chiral moieties. 
Even though results show that DNA may be a target of these complexes, no correlation 
between the interaction with this biomolecule and the biological activity was observed.
Interaction with BSA
Fluorescence experiments. 
Albumin is the most abundant plasma protein and one of its principal functions is the 
transport of drugs, metal ions and/or metal complexes through the blood-stream towards cells 
and tissues. Bovine serum albumin (BSA) is the most commonly used homologue for human 
serum albumin, and the most important protein present in cell culture media used in in vitro 
experiments with mammalian cells, due to the addition of fetal bovine serum (FBS). It 
exhibits intrinsic fluorescence emission due to the presence of phenylalanine, tyrosine and 













































































tryptophan (Trp) residues. Among them, Trp is the dominant intrinsic fluorophore and it can 
be selectively excited at λexc. = 295 nm. BSA contains two Trp residues: Trp134 that is 
located in the proximity of the protein surface and is buried in a hydrophobic pocket of 
domain I and Trp 213 that is located in a hydrophobic binding pocket of subdomain IIA. In 
particular Trp213 is the most sensitive to the local environment and its fluorescence emission 
easily responds to small changes in the vicinity of the indole ring that may occur in response 
to binding to the protein.35 Based on this, the interaction of BSA with the 
[PdII(L3)(dppf)](PF6) complex was studied using fluorescence spectroscopy. Emission 
spectra obtained through titration of BSA with the selected complex are displayed in Fig. 
S13.
The studied complex generated quenching of the fluorescence emission of BSA up to 70 % 
upon increasing its concentration. In addition, the complex induced a red-shift in the 
emission maximum of ca. 4 nm. These results indicate that hydrophobicity increased around 
the Trp213 environment due to the interaction between the protein and the complex.35 
The quenching process was analysed according to Stern-Volmer equation and the binding 
constant (Kbc) and the number of binding site types (n) were calculated from the Scatchard 
equation. The obtained value of KSV was 5.4104 M1 indicating a good BSA fluorescence 
quenching ability for the compound. This KSV value is similar to those previously reported 
for other palladium and platinum complexes that interact efficiently with the protein.77 The 
determined binding constant was Kbc = 6.1103 M1, which is somewhat lower than those 
reported for other metal complexes that interact reversibly with this protein (Kbc in the order 
of 105 M1).77-79 So, the obtained Kbc value is within a nearly optimal range: it is high enough 
for the compounds to bind albumin to be transported but, nevertheless it is sufficiently low to 
let the compound be released from albumin upon arrival to the target.80 The n value obtained 













































































was approximately equal to 1 suggesting the existence of a single binding site type between 
BSA and the M-dppf-L3 complex.
Circular dichroism experiments 
CD spectroscopy is a technique frequently used to monitor protein drug interactions by 
following e.g. changes on the protein CD spectrum. The CD spectrum in the 200–250 nm 
range can yield information on the secondary structure of the protein and on the changes it 
undergoes upon the binding of a compound. However, in the performed experiments, the 
need to use DMSO to solubilise the complexes precluded the use of CD spectroscopy below 
300 nm (due to the DMSO cut-off absorption). In these cases CD can still be a very 
informative technique if ICD bands are observed. The M-dppf-L complexes are CD silent 
species, however they have absorption bands for λ > 300 nm, where BSA does not absorb 
radiation. Therefore, the interaction with BSA can be monitored by the development of ICD 
bands measured above 300 nm, which provide information only on the protein-complex 
bound species that can be formed in solution. Fig. S14 depicts CD spectra of solutions 
containing BSA and the Pd- and Pd-dppf-L complexes measured at 35°C, immediately after 
their addition to a solution containing BSA.
Binding of M-dppf-L complexes to BSA was detected immediately after mixing through the 
development of two main ICD bands. These bands were observed at ~330 nm and ~430 nm, 
in the same wavelength range where the complexes have absorption bands, indicating a fast 
interaction between BSA and the complexes. This interaction proceeds faster than that 
observed for previously studied [Ru2(p-cym)2(L)2]X2 complexes (where X = Cl, PF6; L = 
5-nitrofuryl containing thiosemicarbazone ligands) which, using human serum albumin, 
presented ICD bands only after 1 h of incubation.81 














































































Eight new Pd(II) and Pt(II) heterobimetallic [M(L)(dppf)](PF6) complexes including a 
ferrocenyl moiety were synthesized and fully characterized. The compounds were rationally 
designed by including 5-nitrofuryl containing thiosemicarbazones HL1-HL4 as bioactive 
ligands and a lipophilic and non-toxic ferrocenyl derivative as co-ligand. For the first time 
almost the whole series showed activity in the low micromolar or submicromolar range on 
both parasites and lower toxicity on mammalian cells, as well as higher selectivity towards 
both parasites than the free HL1-HL4 ligands and the several groups of HL classical 
coordination complexes and organometallic compounds previously developed by our group. 
In addition, the in vivo test on zebrafish carried out with the most active compound of the 
series showed no toxicity upon 48 h contact, even for concentrations of 100 μM.
Our data confirmed the biological free radical production capacity of the obtained M-dppf-L 
complexes and subsequent participation in redox processes generating reactive oxygen 
species. Interestingly, the generation of intracellular redox stress in the infective form of 
African trypanosomes was compound specific, suggesting a selective molecular target(s) 
and/or activation pathway for the M-dppf-L complexes. As our CD (and fluorescence) 
measurements indicate that the compounds bind DNA, if the complexes manage to reach this 
biomolecule in the parasite this may also contribute to the toxicity. 
Measurement of circular dichroism spectra also confirmed the binding of the reported M-
dppf-L complexes to BSA. From fluorescence emission quenching obtained with solutions of 
BSA incubated with increasing concentrations of [PdII(L3)(dppf)](PF6) a binding constant of 
ca. 6103 was obtained. This is within the range suitable for being transported in blood by 
albumin, but low enough to let the compound be released upon contact with the target. 













































































Globally these results show that most of these new complexes are promising antiparasitic 
compounds that deserve further studies in the search for prospective broad spectrum 
antitrypanosomal drugs. 
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New heterobimetallic palladium and platinum ferrocenyl derivatives showed 
submicromolar activities on both T. cruzi and T. brucei parasites and high selectivities.
T. cruzi/μM T. brucei/μM SI
[Pt(L3)(dppf)](PF6) 0.76  0.03 0.52  0.03 >50
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